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Abstract: Recently, membrane-active peptides or proteins that include antimicrobial peptides (AMPs),
cytolytic proteins, and cell-penetrating peptides (CPPs) have attracted attention due to their potential applications in the biomedical field. Among them, CPPs have been regarded as a potent
drug/molecules delivery system. Various cargoes, such as DNAs, RNAs, bioactive proteins/peptides,
nanoparticles and drugs, can be carried by CPPs and delivered into cells in either covalent or noncovalent manners. Here, we focused on four arginine-rich CPPs and reviewed the mechanisms
that these CPPs used for intracellular uptake across cellular plasma membranes. The varying transduction efficiencies of them alone or with cargoes were discussed, and the membrane permeability
was also expounded for CPP/cargoes delivery in various species. Direct membrane translocation
(penetration) and endocytosis are two principal mechanisms for arginine-rich CPPs mediated cargo
delivery. Furthermore, the amino acid sequence is the primary key factor that determines the cellular
internalization mechanism. Importantly, the non-cytotoxic nature and the wide applicability make
CPPs a trending tool for cellular delivery.
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1. Introduction
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The plasma membrane is a natural barrier that separates intracellular components from
the external environment and keeps the balance of osmotic pressure. However, membraneactive peptides/proteins disrupt and modulate the integrity of the cell membrane. The
membrane-active peptides are a term for the peptides that are able to interact with lipidbilayer membranes to cause leakage as well as damage on cell membranes or to transport
exogenous molecules into cells [1–3]. Antimicrobial peptides (AMPs), cytosolic peptides and
cell-penetrating peptides (CPPs) are three major types of membrane-active peptides [1,4,5].
Here, we focus on CPPs, which are highly applied in biomedical therapeutics and regarded
as a potent drug delivery system [6].
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2. Cell-Penetrating Peptides (CPPs)

This article is an open access article

Numerous CPPs from natural materials or artificial synthetics were explored in recent
decades [6]. The first CPP, a short peptide containing 11 cationic residues, is referred to as
the protein transduction domain (PTD). This PTD was initially identified from the Tat (transactivator of transcription) protein of the human immunodeficiency virus type 1 (HIV-1) [7,8].
Since then, various CPPs derived from the PTD of the Tat were reported [9]. Up to now,
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1855 CPPs have been defined in CPPsite 2.0, a manually curated database of CPPs [10,11].
Among these 1855 CPPs, 1753 CPPs belong to linear types, whereas 102 CPPs are cyclic
peptides. According to the peptide nature, CPPs were categorized into three major groups:
protein derived, synthetic, and chimeric peptides [11]. However, according to their chemical
and physical properties, most studies have classified CPPs into cationic, amphipathic, and
hydrophobic groups [6]. Both AMPs and CPPs are cationic peptides [6,12]. One of the
differences between AMPs and CPPs is the lengths of amino acid sequences. The length
of AMPs is between 10 and 60 residues and the average number of amino acid residues is
33.26 [12]. Most CPPs contain less than 30 amino acids, but the shortest CPP is a peptide
consisting of five residues (L5a, see Appendix A, Table A1) [13,14]. These CPPs can not only
enter cells by themselves but can also take cargoes with them to cross cell membranes. The
cargoes include proteins/peptides, nucleic acids, peptide nucleic acids (PNA), fluorophores,
nanoparticles, drugs and small molecules [6,11]. The link between CPPs and cargoes can be
covalent [15,16] or noncovalent [17–34], as well as a combination of both (called covalent
and noncovalent protein transductions; CNPT) [35,36]. In order to increase the transduction
efficiency and stability of the cargoes and to decrease the rate of biodegradability, various
strategies of modifications on CPPs were deployed. They include, but are not limited to,
the use of D-form amino acid replacements on β or γ sides [37], cis- or trans-γ-amino acid
modification on branches [38], and non-standard amino acid substitutions [39]. However,
various modifications of the primary sequences of CPPs, types of cargoes for delivery,
combination manners of cargoes, and even concentrations of CPPs were also important
factors in contributing to alternative entry routes into cells [27,30,31,34,38,40].
3. Mechanisms of Cellular Internalization
The understanding of the mechanisms of intracellular uptake for CPPs remains understudied. For example, early research proposed that the Tat protein engaged direct
penetration to enter cells [41]. However, subsequent studies have suggested that both direct
membrane translocation and endocytosis are employed by the Tat to enter cells [42,43].
To date, the proposed mechanisms for CPPs’ entry into cells are divided into two major categories: energy-dependent endocytosis and energy-independent direct membrane
translocation (Figure 1) [44]. Endocytosis of CPPs may involve more than one of the following subtypes: clathrin-mediated endocytosis, caveolae-mediated endocytosis, clathrinand caveolae-independent endocytosis, and macropinocytosis [44,45]. Macropinocytosis
is a kind of F-actin driven lipid raft, which is irrelevant to receptors or any other proteins (Figure 1). It belongs to a non-classical endocytosis [44–46]. Both clathrin-mediated
and caveolae-mediated endocytosis appertain to dynamin-dependent pathways, while
GTPase is involved in all subtypes of endocytosis [45,47,48]. It is arduous to predict the
cellular internalization mechanisms of CPPs simply based on their physical and chemical
properties. Previous studies indicated that most amphipathic CPPs, such as VP22, KALA
and GALA, enter cells via the energy-dependent endocytosis [43]. However, two CPPs,
Pep-1 and MPG, which also belong to amphipathic CPP, use direct penetrations for cellular
entry [43]. Endocytosis and direct membrane translocation have been proposed as the
two major mechanisms used for CPP internalization. Studies were also conducted on
several polyarginines with regard to their induction and shifting between different uptake
mechanisms under various concentrations of CPPs, cargoes, or cell lines [44,49]. Therefore,
in addition to the charge, some critical domains in CPPs were considered as the primary key
to determine cellular entry routes. Cationic polyarginines containing many guanidinium
groups were regarded as specific CPPs, and the term “arginine-magic” was coined [50,51].
In this communication, we focus on four types of arginine-rich CPPs. Nona-arginines were
the backbone of peptide sequences as different modifications or domains were appended
on the backbones. We illustrate the cargoes that four arginine-rich CPPs delivered and the
cellular internalization mechanisms they used in the next subsections.
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Figure 1. Different cellular entry routes for either cell-penetrating peptides (CPPs) alone or
Figure 1. Different cellular entry routes for either cell-penetrating peptides (CPPs) alone or CPP/cargo
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Table 1. Primary sequences of four arginine-rich CPPs and their cellular internalization mechanisms.
CPPs

SR9

Peptide Sequences

Cargoes

Entrance Targets

Mechanisms

References

—

artificial large unilamellar
vesicles (LUVs) in 100 nm
diameter

lipid raft

[54]

plasmid DNAs

RRRRRRRRR

proteins

plant tissues

macropinocytosis

[19]

A549 cells, Sf9 cells, paramecia

unknown

[20,21,23,24,28]

A549 cells, plant epidermal
cells, mouse skin cells

macropinocytosis

[17,22]

A549 cells

multiple pathways

[33,34]

prokaryotes

macropinocytosis

[26]

A549 cells, rotifers, paramecia

unknown

[21,28,29]

A549 cells

direct membrane
translocation

[29]

HEK293T cells, Sf9 cells,
rotifers, paramecia, mice

unknown

[20,21,29,55,56]

rotifers

unknown

[29]

A549 cells

direct membrane
translocation

[25,27,33]

rotifers

unknown

[29]

nanoparticles
—

plasmid DNAs
HR9

CHHHHHRRRR
RRRRRHHHHHC

proteins
nanoparticles

PR9

FFLIPKGRRRRRRRRR

plasmid DNAs

A549 cells, Sf9 cells, paramecia

unknown

[20,21,28,31]

nanoparticles

A549 cells

classical endocytosis

[25,27,31–33]

A549 cells

macropinocytosis

[30]

rotifers

unknown

[29]

A549 cells

classical endocytosis

[30]

rotifers

unknown

[29]

—

IR9

GLFEAIEGFIENG
WEGMIDGWYG
RRRRRRRRR

plasmid DNAs
proteins
nanoparticles

rotifers

unknown

[29]

A549 cells

classical endocytosis

[30]

rotifers

unknown

[29]

3.2. Histidine-Rich Nona-Arginine (HR9)
HR9 CPPs contain extra-modifications with one cysteine and five histidines at both Nand C-termini of the backbone SR9 sequence (Appendix A, Table A1) [27]. Imidazole side
chains on histidines possess additional positive charges and may serve as the hydrogen
donor or acceptor [57]. A higher zeta potential of HR9 allows for a higher degree of cell
membrane disturbance and compactions of HR9/DNA nano-complexes [27,33,55,57,58].
Similar to SR9, HR9 CPPs are able to form complexes with plasmid DNAs, proteins and
nanoparticles, and deliver them into mammalian cells, insect cells, paramecia, rotifers
and mice (Table 1) [20,21,25,27,29,55,56]. Unlike SR9, different cargoes and entry species
play no role in cellular internalization mechanisms of HR9. HR9 CPPs form complexes
with either plasmid DNAs or fluorescent QDs and enter A549 cells by direct membrane
translocation [25,27,29,33]. Zhang et al. designed a histidine- and arginine-rich CPP, NP1
(see Appendix A, Table A1) to deliver anticancer agent ellipticine and found that these
complexes crossed the cell membrane via direct membrane translocation [57]. Although
NP1 is composed of the lipid-like domain, HR9 and NP1 CPPs are all rich in histidine and
arginine residues, suggesting that direct membrane translocation may rely on sufficient
imidazole and guanidinium groups.
3.3. Pas Nona-Arginine (PR9)
Endocytosis may lead to cargo trapping and degradations in lysosome. Modifications
of the SR9 CPPs with lysosomal escape signals become an option when cargoes are delivered by SR9 into cells via either macropinocytosis or multiple endocytic pathways (Table 1).
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An inverted and cleft sequence (FFLIPKG), adopted from a lysosomal aspartyl protease,
cathepsin D, was chosen for the purpose of lysosomal escape, and it was named as a
penetration accelerating sequence (Pas) [59]. PR9 CPPs composed of the SR9 backbone, and
a Pas at the N-terminus are able to deliver plasmid DNAs and nanoparticles into A549 cells,
Sf9 cells, and paramecia via classical endocytosis (Table 1) [20,21,25,27,28,31–33]. Although
nanoparticles delivered by PR9 were co-localized with early endosomes and lysosomes
at the early stage of intracellular trafficking, lysosomal escape and nuclear accumulation
of these fluorescent nanoparticles were observed at the late period of delivery [31–33].
Dual Pas and more arginine addition formed a new CPP, known as the Pas2r12(for primary sequence see Appendix A, Table A1) [60,61]. This CPP can deliver large molecules,
such as enhanced green fluorescent proteins and immunoglobulin G, through caveolaemediated endocytosis, and enhance the release of cargoes to cytosol [60,61]. The ways
in which Pas-CPPs and cargoes interact do not change the entry routes. Glucagon-like
peptide-2 fused with Pas-octa-arginine by covalent bonds can enhance cellular uptake in
A549 and MDCK cells via macropinocytosis, as well as translocate to mouse brains via
intranasal administration [62]. Lysosomal escape and nuclear localization have also been
observed in this Pas-containing arginine-rich CPP [62]. These studies inferred that the
critical domain—Pas—plays the key role in endocytic entry route and lysosomal escape.
The study by Takayama et al. has further supported this hypothesis. In their study, the
Pas domain was replaced by four phenylalanines, and this newly designed F4R8 (primary
sequence in Appendix A, Table A1) increased hydrophobicity, thus promoting membrane
translocations [63].
3.4. INF7 Fusion Nona-Arginine (IR9)
Another endosomolytic peptide—INF7—derived from the influenza hemagglutinin
peptide HA2, was fused with SR9 to enhance endosomal escape and cytosolic release [30].
In another study, various CPPs, such as the Tat and Penetratin, were also fused with
either HA2 or INF7 to compare the membrane lytic properties [64]. INF7 fused with SR9
(called IR9) enters A549 cells by macropinocytosis, but switches to classical endocytosis
when IR9 carries plasmid DNAs or nanoparticles [30]. IR9 can also enter alone or deliver
DNAs or QDs as cargoes in rotifers [29]. While the INF7 domain in IR9 triggers membrane
insertion using highly conserved hydrophobic residues, the polyarginine domain in IR9
executes cellular internalization [65]. Various amino acids in INF7-Tat were replaced for pH
sensitivity studies, and the replacement of glutamic acid at the 6th position of INF7 (A→E)
has enhanced lytic potency at lysosomal pH with marvelous pH selectivity [64]. This
suggested that the glutamic acid replacement in INF7-CPPs only alters acidic lysosomal
membrane without perturbing the cell membrane and, consequently, releases bioactive
molecules into cytosol without any cellular injuries. Interestingly, similar to PR9, IR9
is able to enter cells via endocytosis and escape from lysosome [31,32,64]. INF7-CPPs
are able to alter secondary structures in pH 5.5 and pH 7.0, while PR9 can maintain the
same secondary structures in both pH conditions [31,64]. Many factors, including INF7
positions at either the N- or C-terminus of CPPs, ratios between INF7-CPPs and cargoes,
and the types of cargoes, can affect the cellular uptake efficiencies [30,66,67]. Collectively,
each variable entails unique properties of INF7-infused CPPs, and more extensive studies
are required to identify key variables that are associated with uptake mechanisms and
transduction efficiencies.
4. Evidence of Cellular Internalization
In this communication, we reveal various cargo-delivery capacities and entry mechanisms of four arginine-rich CPPs in various species (Table 1). Although types of cargoes and
penetrating targets influence entry mechanisms, primary sequences play fundamental roles
in cellular internalization. Among these four arginine-rich CPPs, SR9 is the backbone of the
other CPPs (Table 2). The histidine-rich domains added at both ends of SR9 provide more
positive charges, while reverted cathepsin D and INF7 domains give rise to membrane
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disturbance and lysosome escapes. Some peptide properties, such as net charges, hydrophilicities, hydrophobicities, and theoretical pI, were altered due to these modifications.
Table 2. The properties of four arginine-rich CPPs and their additional modified domains.
Net Charge at pH 7.0 1
CPP

Additional Modified
Domain

SR9

—

Hydrophilicity 1

Hydrophobicity 2

pI 2

Full
Sequence

Domain

Full
Sequence

Domain

Full
Sequence

Domain

Full
Sequence

Domain

+9.0

—

3.0

—

0.77

—

13.4

—

HR9

polyhistidine

+9.82

+0.82

0.95

−0.58

−25.32

−6.34

12.8

7.5

PR9

reverted cathepsin D

+9.95

+1.0

1.2

−0.8

19.74

31.52

13.0

10.1

IR9

INF7 domain

+4.0

−5.0

0.6

−0.34

52.25

65.73

11.9

2.8

1

2

Bachem Peptide Calculator. Thermo Fisher Scientific Peptide Analyzing Tool.

Correlations among the structure, properties, mechanism and transduction efficiency
of CPPs are a sophisticated issue due to plenty of variables, such as the types and characteristics of cargoes, targets and primary sequences, as well as the chemical structure
of CPPs. For example, arginine-rich CPPs usually formed complexes with cargoes in
noncovalent manners because of positive/negative charged electrostatic interactions [68].
However, Kamei et al. illustrated that only three cargoes with different pI can be delivered
by octa-arginine (R8), while the other 13 peptide drugs cannot [69]. The pI of cargoes and
the pH value in the environment are irrelevant to cellular internalization efficiencies. In
contrast, the chemical structures, such as L- and D-form, affect cellular internalization
efficiencies [70,71]. D-form CPPs are resistant to enzymatic digestions and possess higher
stability, which creases cellular internalization [70,71]. Primary sequences of CPPs alter
not only cellular internalization efficiencies but also entry mechanisms. While different
modified CPPs complexed with or without QDs as the variants, significant differences in
cellular internalization efficiencies were observed [25,27,29,33]. The highest efficiency was
observed in HR9/QD complexes, while the poor transduction efficiency was displayed in
IR9/QD at the same combination ratio of 60 [33]. The INF7 domain in IR9 contributes the
highest scale of hydrophobicity and negative charges (Table 2). Therefore, added domains
on the SR9 backbone play an important role in determining CPP primary sequences and
their transduction efficiencies. Peptide lengths also define the protein transduction efficiencies [70]. The highest insulin absorption is enhanced by R8, instead of 6 or 10 arginine
residues [70].
5. Conclusions
CPPs have been recognized as a promising tool for intracellular deliveries of bioactive
molecules due to their high cellular internalization efficiency. Arginine-rich CPPs are the
most common membrane active peptides in biomedical applications. We described unique
properties of four arginine-rich CPPs and their capability to internalize a variety of cargoes
using different uptake mechanisms. By manipulating their structures, lysosomal escape
can be achieved and higher efficiency can be accomplished. A greater understanding of
correlations among structures, properties, mechanisms and transduction efficiencies can
certainly facilitate the design of more effective CPPs for broader applications in the future.
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Appendix A
Table A1. Primary Sequences of cell-penetrating peptides.
CPP

Primary Sequence

F4R8
HR9
IR9
L5a
NP1
Pas2r12
PR9
SR9

FFFFGRRRRRRRRGC
CHHHHHRRRRRRRRRHHHHHC
GLFEAIEGFIENGWEGMIDGWYGRRRRRRRRR
RRWQW
stearyl-HHHHHHHHHHHHHHHHRRRRRRRR-NH2
FFLIGFFLIGRRRRRRRRRRRR
FFLIPKGRRRRRRRRR
RRRRRRRRR
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